PrEP

A report suggests that addressing financial barriers to antiretroviral therapy adherence may improve levels of viral suppression.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has approved Descovy (emtricitabine 200-mg and tenofovir alafenamide 25-mg tablets) for HIV-1 pre-exposure prophylaxis (PrEP).

National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.

California has passed SB 159, becoming the first state allowing pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription. Supporters say the legislation will greatly reduce the spread of infection.1

TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.

Top news of the day from across the health care landscape.

The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.

London Mayor Sadiq Khan has called for broader availability of pre-exposure prophylaxis drugs in his welcoming speech at the Fast-Track Cities 2019 conference, where leaders from 300 cities around the world will discuss municipal responses to HIV, tuberculosis, and viral hepatitis.

In recent months, legislation to increase access to pre- and post-exposure prophylaxis (PrEP and PEP) passed in California with a vote of 34-1 in the Senate and a unanimous vote in the Assembly.

An FDA committee has recommended approval of Gilead’s Descovy to reduce the risk of sexually acquired HIV infection in those at high risk of acquiring the virus.

An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.

Pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection in individuals at high risk.

Top news of the day from across the health care landscape.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

Top news of the day from across the health care landscape.

Health care professionals, including pharmacists and nurse practitioners, play a critical role in attaining goals for reducing HIV transmission.

Due to physician shortages, pharmacists represent a new avenue to increase accessibility to antivirals.

Introduced by U.S. Senator Kamala D. Harris (D-CA), the bill requires all insurance plans to cover HIV prevention medications and services without out-of-pocket costs. The bill also facilitates access to PrEP for uninsured individuals.

Top news of the day from across the health care landscape.

Expansion to adolescents, flexible dosing strategies, innovative delivery models, and long-acting antiretrovirals all help the strategy.

An agreement between the US Department of Health and Human Services and Gilead will provide HIV prevention drugs to uninsured individuals who are at risk.

Top news of the day from across the health care landscape.

Overall, more than half of commercially insured individuals who initiated pre-exposure prophylaxis persisted with it for the 12-month duration of the cohort study.